Alzheimer s & Dementia,
Journal Year:
2023,
Volume and Issue:
19(7), P. 3233 - 3234
Published: April 20, 2023
Abstract
Although
there
is
a
clear
link
between
lifestyle
and
cognitive
health,
the
dissonance
observational
intervention
studies
results
reveals
gaps
in
knowledge
of
how
to
translate
healthy
lifestyles
into
better
health
for
population.
This
letter
discusses
interpreting
linking
older
adults.
The
main
goal
briefly
highlight
necessity
understanding
incorporating
intrinsic
extrinsic
drivers
engagement
before
prescribing
implementing
individual
multicomponent
programs.
European Journal of Epidemiology,
Journal Year:
2024,
Volume and Issue:
39(2), P. 161 - 169
Published: Jan. 5, 2024
Abstract
The
mixed
evidence
of
the
association
between
high
levels
cardiovascular
risk
factors
(CVRF)
and
for
cognitive
impairment
may
be
due
to
confounding
age
across
studies.
We
pooled
harmonized
individual-level
data
(30,967
persons,
range
42–96
years)
from
five
prospective
cohorts
investigate
by
1
year
increments
whether
or
not
there
is
change
in
slope
describing
CVRF
a
outcome
(Digit
Symbol
Substitution
Test;
DSST).
included:
systolic
diastolic
blood
pressure,
total
cholesterol,
fasting
glucose
body
mass
index.
Linear
quadratic
piecewise
regression
models
were
fit
trajectory
patterns
these
slopes
(betas).
pattern
yearly
changes
showed
higher
associated
with
lower
DSST,
but
associations
attenuated
toward
zero
as
increased
all
DBP
where
changed
direction
negative
positive
mid-
late-age.
Age
only
driver
decline—age
also
modifies
strength
function
cohort
one
reason
why
CVRF-CD
mixed.
Expert Opinion on Emerging Drugs,
Journal Year:
2024,
Volume and Issue:
29(1), P. 35 - 43
Published: Jan. 2, 2024
Introduction
Monoclonal
antibodies
targeting
amyloid-β
are
the
first
disease-modifying
treatments
for
Alzheimer
disease
to
have
received
FDA-approval.
There
three
different
drugs
approved
or
pending
FDA-approval:
aducanumab,
lecanemab,
and
donanemab.
These
each
in
stages
of
regulatory
approval
by
FDA.
Alzheimer s & Dementia,
Journal Year:
2024,
Volume and Issue:
20(7), P. 4625 - 4634
Published: June 2, 2024
Recent
growth
in
the
functionality
and
use
of
technology
has
prompted
an
increased
interest
potential
for
remote
or
decentralized
clinical
trials
dementia.
There
are
many
benefits
associated
with
medication
trials,
but
we
currently
lack
specific
recommendations
their
delivery
dementia
field.
Alzheimer s & Dementia,
Journal Year:
2023,
Volume and Issue:
19(7), P. 3233 - 3234
Published: April 20, 2023
Abstract
Although
there
is
a
clear
link
between
lifestyle
and
cognitive
health,
the
dissonance
observational
intervention
studies
results
reveals
gaps
in
knowledge
of
how
to
translate
healthy
lifestyles
into
better
health
for
population.
This
letter
discusses
interpreting
linking
older
adults.
The
main
goal
briefly
highlight
necessity
understanding
incorporating
intrinsic
extrinsic
drivers
engagement
before
prescribing
implementing
individual
multicomponent
programs.
